Dr Padideh Kamali-Zare
Darmiyan will offer a series of diagnostic tools aimed at early detection of complex brain diseases including neurodegenerative disorders. Darmiyan will get brain MRI data from human patients to elucidate the current condition, and which disease state the brain is progressing toward. The significance of Darmiyan’s innovation is invaluable potential to diagnose disease potential before severe symptoms develop. This novel insight originates with our technology to extract information not from the brain cells/ neurons, which exhibit abnormality only after extensive damage and cell death occurs, but from the immediate environment around them, which is called extracellular space (ECS). The ECS is often thought of as just intercellular “space,” but in reality it is the electrical and chemical pathway between all brain cells that plays an essential role in brain function and drug delivery.
BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women’s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world.
Our client retention is unparalleled in the industry because we are much more than just the provider of quality diagnostics. We have grown primarily as a result of our differentiating business model which is both physician-centric – providing superior service and support – and clinically relevant – providing innovative and disruptive technology to improve patient outcomes. What makes us different from other labs is the added value we bring through personal attention and professional support and the effort we make to understand our clients’ needs. Our success comes from helping clinicians deliver premium services to the patients in their care – through a full menu of cost–conscious testing options and cutting edge technologies with clinically–relevant results, all in a medically and fiscally responsible manner.
In addition, BioReference has pioneered the development of business solutions for our clients, providing data and analytics to help them operate at their fullest potential.
The Laboratory services multiple markets through several specialized business units, each with its own dedicated sales team and highly-trained support personnel. These include women’s health, oncology, genetics and a lab division focused exclusively on the nation’s expanding Spanish-speaking populations.
Clinical Diagnostics, Oncology, Women's Health, Genetic Testing
a US based accounting and tax services firm with American Certified Public Accountants (CPAs) and French diplomes Experts-comptables (French CPA licensees).
KVB Partners, with multi-lingual staff, joins its effort with a common goal:
Assisting European companies to develop their activities in North America
Our fields of expertise:
• International Taxation
• Business Development.
Arnaud Sinan KARABOGA
Finding new uses of safe drugs based on polypharmacology profiling: Armonco® a clinical candidate for lung cancer.
OBJECTIVES FOR THIS EVENT
Harmonic Pharma is looking for a company which would be interested in acquiring the exclusive license of Armonco® in order to perform its clinical development in lung cancer.
TECHNOLOGY AND PRODUCTS
Harmonic Pharma has developed a unique and innovative know-how combining polypharmacology with relevant animal models mimicking human diseases. This expertise has been applied to identify a clinical candidate for lung cancer from existing safe drugs: Armonco® has been developed to be licensed out for a clinical trial.
New targeted therapy for lung cancer
Armonco® acting in monotherapy and in combination with existing treatments including inhibitor antibodies
Clinical candidate with already well documented safety in man
Cost-effective process and shortening time to market
Consolidated IP including a specific formulation
Ø Seeking companies interested in discussing common business opportunities in the cancer area
Dr Ramesh Kashi
MERCKSenior Principal Scientist
In 2014 we continued to build on our legacy of above market performance by strengthening our leadership in Orthopaedics, Medical and Surgical (MedSurg) and Neurotechnology & Spine. We delivered solid growth and financial results, completed a number of acquisitions, opened a new European Regional Headquarters (RHQ) and articulated our unique culture through a new mission statement and core values.
Stryker CorporationVP, Intellectual Property Business Strategy
Based on the corporate philosophy of "Takeda-ism" (Integrity: Fairness, Honesty and Perseverance) developed over its long corporate history of more than 230 years, Takeda conducts activities according to the corporate mission to “strive towards better health for people worldwide through leading innovation in medicine.”
Takeda PharmaceuticalsSr. Director, Center for External Innovation
Dr Abdulkadir Keskinaslan
Novartis Pharma AG provides treatments for Alzheimer’s disease, Parkinson’s disease, Attention-Deficit/Hyperactivity Disorder, epilepsy, schizophrenia, and migraine. It is also developing a treatment for type 2 diabetes; drugs therapies that improve insulin action to increase glucose disposal in the muscle, to limit its production in the liver, and to improve the kinetics of insulin secretion; and oral and physiological approach to enhancing glucagon like peptide-1 activity, which acts to stimulate insulin secretion and inhibit glucagon production. The company is based in Basel, Switzerland. Novartis Pharma AG operates as a subsidiary of Novartis AG
Novartis Pharma AGHead MA & EA TR
Dr Daniel Klamer
Anavex™ Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer, which have significant unmet medical needs.
ANAVEX™ 2-73, the Company’s orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.
A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®). The combined therapeutics, referred to as “ANAVEX™ PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.
ANAVEX PLUS is believed to be a compelling commercial opportunity. The clinical trial risk is lower because donepezil (Aricept®) is already on the market, with global sales of $4-billion annually. Donepezil (Aricept®) is now generic and a patent application has been filed for ANAVEX PLUS which, if granted, would provide protection until 2033.
Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.